Search company, investor...

Syndexa Pharmaceuticals

syndexa.com

Founded Year

2007

Stage

Dead | Dead

Total Raised

$23.98M

About Syndexa Pharmaceuticals

Syndexa Pharmaceuticals is dedicated to the discovery and development of drugs targeting biological mechanisms for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and cardiovascular disease. The principal scientific and product platforms of Syndexa target the biological interface between inflammatory and metabolic pathways with unique tools and apporaches.

Headquarters Location

48- Arsenal Street Building 1

Watertown, Massachusetts, 02472,

United States

Missing: Syndexa Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Syndexa Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Syndexa Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syndexa Pharmaceuticals is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,899 items

Latest Syndexa Pharmaceuticals News

Syndexa Pharmaceuticals Adds to B1 Round

Jan 5, 2012

Syndexa Pharmaceuticals Adds to B1 Round January 5, 2012 Watertown, Mass.-based Syndexa Pharmaceuticals Corp. has raised an undisclosed amount of Series B1 financing from MP Healthcare Venture Management. Total capital raised in the B1 round was $8.5 million. Syndexa is developing drugs to treat metabolic diseases. PRESS RELEASE Syndexa Pharmaceuticals Corp., a biopharmaceutical company developing first-in-class drugs to treat metabolic diseases, announced today that it has secured additional Series B1 financing from MP Healthcare Venture Management (MPH), a jointly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Chemical Holdings Corporation (MCHC). Total capital raised in the Series B1 round, which was originally led by existing investor Dr. Yalcin Ayasli in April 2011, now stands at $8.5 million. In conjunction with the Series B1 transaction, Tetsuro Iwata will represent MPH as an Observer on Syndexa’s Board of Directors. “The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction.” “This funding from new investor, MP Healthcare Venture Management, and support from Tetsuro Iwata comes at an important time for Syndexa,” said Teo Uysal, President and CEO. “The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction.” About MP Healthcare Venture Management MP Healthcare Venture Management, Inc. (MPH) is a lifesciences venture capital firm, investing in innovative companies developing novel therapeutics, platform technologies, vaccines and diagnostics. MPH invests in seed to late stage private companies, and investment is not limited by geographic region. MPH is a jointly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Chemical Holdings Corporation (MCHC). For more information, visit www.mp-healthcare.com. About Syndexa Pharmaceuticals Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting novel mechanisms for the treatment and prevention of diseases of endoplasmic reticulum (ER) dysfunction which include inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases. Founded by leading scientists from Harvard University, the company has raised $24.8M of equity capital to date and is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Watertown, MA. © 2015 Buyouts Insider / Argosy Group LLC

Syndexa Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Syndexa Pharmaceuticals founded?

    Syndexa Pharmaceuticals was founded in 2007.

  • Where is Syndexa Pharmaceuticals's headquarters?

    Syndexa Pharmaceuticals's headquarters is located at 48- Arsenal Street, Watertown.

  • What is Syndexa Pharmaceuticals's latest funding round?

    Syndexa Pharmaceuticals's latest funding round is Dead.

  • How much did Syndexa Pharmaceuticals raise?

    Syndexa Pharmaceuticals raised a total of $23.98M.

  • Who are the investors of Syndexa Pharmaceuticals?

    Investors of Syndexa Pharmaceuticals include Dr. Yalcin Ayasli, MP Healthcare Venture Management and Qualifying Therapeutic Discovery Project.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.